HC Wainwright reiterated their buy rating on shares of pSivida (NASDAQ:PSDV) in a report released on Tuesday, January 9th. HC Wainwright currently has a $5.00 target price on the stock.
Other equities analysts have also recently issued reports about the stock. B. Riley set a $5.00 price objective on shares of pSivida and gave the stock a buy rating in a research note on Friday, December 15th. ValuEngine cut shares of pSivida from a sell rating to a strong sell rating in a research note on Friday, December 1st. Laidlaw started coverage on shares of pSivida in a research note on Wednesday, November 8th. They issued a buy rating and a $5.00 price objective for the company. Finally, Northland Securities reissued a buy rating and issued a $10.00 price objective on shares of pSivida in a research note on Monday, December 11th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. pSivida currently has a consensus rating of Buy and an average target price of $7.57.
pSivida (NASDAQ PSDV) traded down $0.01 on Tuesday, reaching $1.10. 410,156 shares of the company traded hands, compared to its average volume of 429,293. The stock has a market capitalization of $49.78, a PE ratio of -2.39 and a beta of 1.27. pSivida has a 52 week low of $1.02 and a 52 week high of $2.45.
pSivida (NASDAQ:PSDV) last posted its earnings results on Tuesday, November 7th. The company reported ($0.15) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.15). The company had revenue of $0.39 million during the quarter, compared to analysts’ expectations of $0.74 million. pSivida had a negative net margin of 226.31% and a negative return on equity of 139.56%. analysts forecast that pSivida will post -0.59 EPS for the current year.
A hedge fund recently bought a new stake in pSivida stock. OxFORD Asset Management LLP acquired a new stake in shares of pSivida Corp. (NASDAQ:PSDV) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned approximately 0.18% of pSivida at the end of the most recent reporting period. 9.70% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “pSivida’s (PSDV) “Buy” Rating Reiterated at HC Wainwright” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/05/hc-wainwright-reiterates-buy-rating-for-psivida-psdv.html.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.